Beta-Cell - Liver Interactions in Situations of Modified Beta-Cell Function
Recruiting · NCT06682481 · Observational (researchers observe without assigning treatment) · Lead sponsor: Philippe Klee, MD-PhD
View the official record on ClinicalTrials.gov →Interventions studied
Measurement of biomarker
What this trial is about
The investigators will measure blood levels of 1,5-anhydroglucitol in obese children with or without type 2 diabetes and correlate them with parameters related to functional beta-cell mass and glucose metabolism. The values will be compared to those obtained in healthy volunteers. The aim of the study is to test the validity of 1,5-anhydroglucitol as a novel biomarker of beta-cell mass and function in children with obesity with or without type 2 diabetes.
Who can take part
Age range
12 Years to 16 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Children aged 12 to 16 years
- Obesity. Defined as a body-mass index above the 97th percentile.
- Ability to give informed consent as documented by signature
Exclusion criteria
- Patients with diabetes mellitus and positive autoantibodies against islets, insulin, islet antigen 2, glutamic acid decarboxylase or Zinc transporter 8.
- Patients with known liver disease (other than NAFLD)
- Patients treated with an oral antidiabetic drug, glucagon-like peptide-1 analogues or insulin at the time of or less than 2 weeks prior to inclusion.
- Patients treated with a drug known to affect liver function
Where it is running
1 location listed.
- University Hospital of Geneva - Geneva, Canton of Geneva, Switzerland